Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/2/2021 | $44.00 → $41.50 | Market Outperform | JMP Securities |
| 11/1/2021 | $12.00 | Neutral → Buy | Chardan Capital Markets |
| 6/23/2021 | $36.00 → $38.00 | Market Outperform | JMP Securities |
| 6/23/2021 | $28.00 | Overweight | Cantor Fitzgerald |
CAMBRIDGE, Mass., March 17, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (NASDAQ:EVLO), a clinical stage biotechnology company developing SINTAX™ medicines as a new modality of orally delivered treatments for inflammatory disease, today announced that it will host a conference call and live webcast at 8:30 a.m. ET on Thursday, March 24, 2022 to report its fourth quarter and full year 2021 financial results and discuss business highlights. To access the live conference call, please dial 866-795-3242 (domestic) or 409-937-8909 (international) and refer to conference ID 6076311. A live webcast of the event will also be available under "News and Events" in the Investors section of Eve
CAMBRIDGE, Mass., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (NASDAQ:EVLO), a clinical stage biotechnology company developing SINTAX™ medicines as a new modality of orally delivered treatments for inflammatory disease, today announced that it will host a conference call and live webcast at 8:30 a.m. ET on Thursday, October 28, 2021, to report its third quarter 2021 financial results and discuss business highlights. To access the live conference call, please dial 866-795-3242 (domestic) or 409-937-8909 (international) and refer to conference ID 7574834. A live webcast of the event will also be available under "News and Events" in the Investors section of Evelo's website at h
CAMBRIDGE, Mass., July 22, 2021 (GLOBE NEWSWIRE) -- Evelo Biosciences (NASDAQ:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines, today announced that it will host a conference call and live webcast at 8:30 a.m. ET on Thursday, July 29, 2021, to report its second quarter 2021 financial results and discuss business highlights. To access the live conference call, please dial 866-795-3242 (domestic) or 409-937-8909 (international) and refer to conference ID 1658301. A live webcast of the event will also be available under "News and Events" in the Investors section of Evelo's website at http://ir.evelobio.com. The archived webcast will be ava
Chris Schade appointed as Board ChairpersonLynne Parshall, Robert Plenge, M.D., Ph.D., and Nancy Simonian, M.D., appointed to Board of DirectorsCAMBRIDGE, Mass., July 17, 2024 /PRNewswire/ -- Alltrna, a Flagship Pioneering company unlocking transfer RNA (tRNA) biology and pioneering tRNA therapeutics to regulate the protein universe and resolve disease, today announced the appointment of Chris Schade, Growth Partner at Flagship Pioneering, as Chairperson of the Board, succeeding Noubar Afeyan, Ph.D., Co-Founder of Alltrna and Founder and CEO of Flagship Pioneering. In addition, Alltrna also announced the appointments to the company's Board of Directors of Lynne Parshall, founding Chief Opera
– EDP2939 Phase 2 trial in moderate psoriasis fully enrolled with topline data expected early Q4 2023– Completed $25.5 Million Private Placement– Restructured and reduced secured debt with Horizon Technology Finance Corporation CAMBRIDGE, Mass., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (NASDAQ:EVLO), ("Evelo" or the "Company") a clinical stage biotechnology company developing a novel platform of orally delivered inflammation-resolving medicines acting on the small intestinal axis (SINTAX), today announced its second quarter 2023 financial results and recent business highlights. Simba Gill, Ph.D., Evelo's Chief Executive Officer, said, "We are on track for a top line read
Restructures and reduces secured debt with Horizon Technology Finance Corporation Appoints two new members and decreases size of Board of Directors CAMBRIDGE, Mass., July 12, 2023 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (NASDAQ:EVLO) (the "Company" or "Evelo"), a clinical stage biotechnology company developing a novel platform of orally delivered inflammation-resolving medicines acting on the small intestinal axis (SINTAX), today announces that it closed the previously announced private placement, resulting in gross proceeds of approximately $25.5 million from the sale of 11,025,334 shares of its common stock at a purchase price of $2.31 per share. The offering was led by Evelo's fo
Chris Schade appointed as Board ChairpersonLynne Parshall, Robert Plenge, M.D., Ph.D., and Nancy Simonian, M.D., appointed to Board of DirectorsCAMBRIDGE, Mass., July 17, 2024 /PRNewswire/ -- Alltrna, a Flagship Pioneering company unlocking transfer RNA (tRNA) biology and pioneering tRNA therapeutics to regulate the protein universe and resolve disease, today announced the appointment of Chris Schade, Growth Partner at Flagship Pioneering, as Chairperson of the Board, succeeding Noubar Afeyan, Ph.D., Co-Founder of Alltrna and Founder and CEO of Flagship Pioneering. In addition, Alltrna also announced the appointments to the company's Board of Directors of Lynne Parshall, founding Chief Opera
Restructures and reduces secured debt with Horizon Technology Finance Corporation Appoints two new members and decreases size of Board of Directors CAMBRIDGE, Mass., July 12, 2023 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (NASDAQ:EVLO) (the "Company" or "Evelo"), a clinical stage biotechnology company developing a novel platform of orally delivered inflammation-resolving medicines acting on the small intestinal axis (SINTAX), today announces that it closed the previously announced private placement, resulting in gross proceeds of approximately $25.5 million from the sale of 11,025,334 shares of its common stock at a purchase price of $2.31 per share. The offering was led by Evelo's fo
Cellarity, a life sciences company founded by Flagship Pioneering to transform the way medicines are created, announced today the appointment of Gregory J. Moore, M.D., Ph.D., to the Company's Board of Directors. As the former Corporate Vice President for Microsoft, leading global health and life sciences, Dr. Moore brings extensive experience and expertise in integrating R&D, AI and machine learning, and cloud and data technologies to positively transform companies within the health and life sciences ecosystem. "Greg is an industry leader, driving technology and life sciences innovation at the intersection of medical and large-scale computation," said Stephen Berenson, Chairman of Cellar
4 - Evelo Biosciences, Inc. (0001694665) (Issuer)
4 - Evelo Biosciences, Inc. (0001694665) (Issuer)
4 - Evelo Biosciences, Inc. (0001694665) (Issuer)
SC 13G/A - Evelo Biosciences, Inc. (0001694665) (Subject)
SC 13G/A - Evelo Biosciences, Inc. (0001694665) (Subject)
SC 13G - Evelo Biosciences, Inc. (0001694665) (Subject)
JMP Securities reiterated coverage of Evelo Biosciences with a rating of Market Outperform and set a new price target of $41.50 from $44.00 previously
Chardan Capital Markets upgraded Evelo Biosciences from Neutral to Buy and set a new price target of $12.00
JMP Securities reiterated coverage of Evelo Biosciences with a rating of Market Outperform and set a new price target of $38.00 from $36.00 previously
EFFECT - Evelo Biosciences, Inc. (0001694665) (Filer)
15-12G - Evelo Biosciences, Inc. (0001694665) (Filer)
S-8 POS - Evelo Biosciences, Inc. (0001694665) (Filer)
Gainers Phio Pharma (NASDAQ:PHIO) stock increased by 33.9% to $1.5 during Wednesday's pre-market session. The company's market cap stands at $3.6 million. Tenax Therapeutics (NASDAQ:TENX) shares moved upwards by 18.41% to $0.4. The market value of their outstanding shares is at $9.4 million. Brainstorm Cell (NASDAQ:BCLI) stock rose 18.0% to $0.36. The market value of their outstanding shares is at $17.6 million. Altamira Therapeutics (NASDAQ:CYTO) stock rose 17.45% to $0.43. The market value of their outstanding shares is at $3.3 million. Rani Therapeutics Hldgs (NASDAQ:RANI) shares moved upwards by 15.41% to $2.62. The company's market cap stands at $67.8 million. Minerva Surgical (NA
Gainers GeneDx Hldgs (NASDAQ:WGS) stock moved upwards by 39.7% to $1.97 during Friday's regular session. The market value of their outstanding shares is at $50.9 million. Scilex Holding (NASDAQ:SCLX) stock increased by 27.72% to $1.29. The company's market cap stands at $123.6 million. Modular Medical (NASDAQ:MODD) shares rose 21.69% to $1.29. The company's market cap stands at $27.2 million. Sight Sciences (NASDAQ:SGHT) stock rose 18.0% to $2.95. The company's market cap stands at $143.8 million. Gyre Therapeutics (NASDAQ:GYRE) shares increased by 17.62% to $18.95. The company's market cap stands at $1.4 billion. Pasithea Therapeutics (NASDAQ:KTTA) stock moved upwards by 16.66% to $0.